(DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 08 May 2026
Net transaction value: -$51,197
SEC form: 4
Accepted by SEC: 11 May 2026, 17:00:13 UTC
Prior SEC filing: 01 Apr 2026
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Veness, as attorney-in-fact for Paula Soteropoulos

Key filing fact

Paula Soteropoulos filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 11 May 2026.

Key facts

This page summarizes Paula Soteropoulos's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 May 2026, 17:00.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: -$51,197.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001692444 Primary reporting owner

Soteropoulos Paula

Relationship: Director
Address: C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK
Signature: /s/ Adam Veness, as attorney-in-fact for Paula Soteropoulos
Signature date: 11 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNTH transaction

Common Stock

Options Exercise

Transaction value
Shares: +599
Change %
Price: $8.44^*
Shares after: 599
Date: 08 May 2026
Ownership: Direct
Footnotes: F1

DNTH transaction

Common Stock

Sale

Transaction value: $51,197
Shares: -599
Change %: -100%
Price: $85.47
Shares after: 0
Date: 08 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -599
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 08 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 599
Exercise price: $8.44
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.

Footnote F2

The shares of common stock underlying this stock option award vested as to 25% of the shares on April 6, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.